Colltech begins work on extraction plant
01 September, 2004 by Graeme O'NeillIf Australia rides on the sheep’s back, new Perth biotech CollTech (ASX:CAU) is capitalising on what lies just beneath the golden fleece: collagen-rich sheepskin.
Medimmune stops arthritis and psoriasis trials
31 August, 2004 by Staff WritersMaryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.
In brief: Agenix files for Canadian trials; Rockeby to appoint Chinese distributor
31 August, 2004 by Renate KrelleBrisbane’s Agenix (ASX: AGX, NASDAQ OTC: AGXLY) announced today it had filed a Clinical Trial Application (CTA) with Health Canada in preparation for the Phase II clinical trials of its ThromboView blood clot imaging technology.
ChemGenex and UK’s Vernalis sign $2m partnership
31 August, 2004 by Graeme O'NeillDeakin University molecular geneticist Professor Greg Collier was right on the mark when he chose the chubby Israeli sand rat as a model species for his quest for susceptibility genes for non insulin-dependent diabetes.
Investors stampede out of Chemeq
30 August, 2004 by Graeme O'NeillThe share price of Perth veterinary drug-developer Chemeq Ltd (ASX:CMQ) lost over 25 per cent of its value when the company resumed trading today after a two-week voluntary suspension.
Biota winds back loss, despite legal expenses
30 August, 2004 by Renate KrelleMelbourne-based Biota (ASX:BTA) has reported a loss of $7.8 million, down 25 per cent from its 2003 loss of $10.3 million. This is despite a hefty legal bill of just under $1 million for Biota’s lawsuit against marketing partner GlaxoSmithKline for failure to promote its influenza drug, Relenza.
Agenix files IND, announces $14.3m loss
30 August, 2004 by Renate KrelleBrisbane’s Agenix [ASX: AGX, NASDAQ OTC: AGXLY] has filed an Investigational New Drug application with the US Food and Drug Administration for its blood clot imaging technology, Thromboview.
Solid Progen looking to bolster pipeline
30 August, 2004 by Graeme O'NeillBrisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) has reported a reduced net loss of AUD$4.8 million for the year to June 30, down from $7.6 million in 2003, after increasing revenues by 8.6 per cent.
Impressive ASX debut for Somnomed
27 August, 2004 by Melissa TrudingerSleep device company Somnomed (ASX: SOM) made an impressive debut on the ASX today, opening 30 per cent above the IPO issue price of AUD$0.30 at $0.40.
Antisense reports reduced loss, good cash reserves
27 August, 2004 by Melissa TrudingerAntisense Therapeutics (ASX: ANP) has ended the financial year in great shape, as it plans to move forward on Phase IIa clinical trials following the completion of Phase I safety studies.
Living Cell Technologies closes IPO
27 August, 2004 by Melissa TrudingerLiving Cell Technologies has closed its IPO after raising AUD$6.36 million from institutional and retail clients of underwriting stockbroker Taylor Collinson.
Starpharma reigns in losses
27 August, 2004 by Melissa TrudingerStarpharma Holdings (ASX: SPL) has reported a reduced loss of AUD$5.5 million compared to last year's loss of $7.7 million, despite a slight drop in revenues.
CSL triples profit
26 August, 2004 by Staff WritersCSL, the world's largest maker of human plasma products, tripled its annual net profit with the sale of its animal health business and its purchase of Aventis Behring at a discount to asset value.
Prana loss rises to $10m, as R&D spend increases
26 August, 2004 by Graeme O'NeillMelbourne brain-disease drug-discovery company Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) has reported an after-tax loss of $9.9 million in the year to June.
Ambri’s SensiDx still on trial
26 August, 2004 by Graeme O'NeillSydney’s Ambri Technology (ASX:ABI) has announced a net operating loss of $11.4 million for 2004, 35 per cent below last year’s loss of $17.6 million. The company also said earlier this week that its SensiDx ion-channel pregnancy test sensor had yet to meet the full requirements of a commercial viability trial (CVT) in a clinical setting.
